Reported 1 day ago
The obesity drug market remains competitive, with Eli Lilly leading the way with its Zepbound drug, while Novo Nordisk faces challenges amid disappointing results. Investors are keenly watching developments from companies like Zealand Pharma and Viking Therapeutics as the market potentially expands to $130 billion by 2030. In 2025, the focus will be on new clinical data that could clarify long-term winners in this lucrative sector.
Source: YAHOO